This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy?
by Shaun Pruitt
Shares of Moderna (MRNA) and Merck (MRK) are soaring Wednesday after the companies reported a potentially historic breakthrough for their personalized mRNA cancer vaccine.
MRKPositive Net Change MRNAPositive Net Change
biotechnology cancer cell-therapy dividends genetics hospitals immuno-therapy investing large-cap medical pharmaceuticals
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
by Zacks Equity Research
Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.
CYTKNegative Net Change BMYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
by Ekta Bagri
Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
LQDANegative Net Change JNJPositive Net Change UTHRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Elite Pharmaceuticals Stock Plunges Post Q1 Earnings, Revenues Fall Y/Y
by Zacks Equity Research
ELTP's first-quarter fiscal 2027 revenues decline as generic competition and lower pricing offset higher volumes, while pipeline development remains a growth focus.
ELTPNegative Net Change
earnings medical pharmaceuticals
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
by Ahan Chakraborty
Eli Lilly's GLP-1 portfolio outpaces its rival in Q2, while Foundayo gains momentum and can challenge Wegovy's early oral obesity lead.
LLYPositive Net Change NVOPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer's Obesity Push: Can Berobenatide Take Market Share?
by Kinjel Shah
PFE aims to break into the obesity market with berobenatide, a potential monthly treatment designed to compete with leading GLP-1 therapies.
PFEPositive Net Change AZNPositive Net Change NVOPositive Net Change LLYPositive Net Change
pharmaceuticals
Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.
TEVAPositive Net Change REGNPositive Net Change SNYPositive Net Change JNJPositive Net Change
pharmaceuticals
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment
by Zacks Equity Research
BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.
BMRNNegative Net Change AZNPositive Net Change RGENPositive Net Change ANIKPositive Net Change
biotechs medical pharmaceuticals
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
by Ekta Bagri
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
GILDPositive Net Change GSKPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
by Zacks Equity Research
AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.
AZNPositive Net Change MRKPositive Net Change HCMPositive Net Change
biotechs medical pharmaceuticals